


Exscientia inks €37m contract with GSK

03 July 2017 | News

According to the agreement, GSK will pay all research costs



GlaxoSmithKline has secured access to Ex Scientia Ltd (Exscientia)'s artificial intelligence (AI)-driven drug discovery platform.

GSK said in a statement that, "It will nominate up to 10 targets for small molecule discovery by Exscienta's platform, which identifies mono- and bispecific small molecule drugs by phenotypic and high content screening and uses artificial intelligence-driven algorithms to design novel molecules"

According to the agreement, GSK will pay all research costs. Additionally, Exscienta can receive up to £33m (€37m) in milestone payments for lead discovery and preclinical development. No further financial details have been disclosed.

According to Andrew Hopkins, CEO, Exscienta's, "The deal with GSK provides further validation of our Al-driven platform and its potential to accelerate the discovery of novel, high-quality drug candidates. Applying our approach to client discovery projects has already delivered candidate-quality molecules in roughly one-quarter of the time, and at one-quarter of the cost of traditional approaches. Our intention therefore is to apply these capabilities to projects selected by GSK."